Loading...
Loading...
Valeant Pharmaceuticals
International, Inc.
VRX announced that the applicable
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976
("HSR") with respect to the previously announced tender offer by its indirect
wholly-owned subsidiary, Odysseus Acquisition Corp. ("Purchaser"), for all of
the outstanding shares of common stock of Obagi Medical Products, Inc.
OMPI ("Obagi") at a price of $24.00 per share, net to the seller in
cash, without interest (less any required withholding taxes) and subsequent
merger of Purchaser with Obagi expired at 11:59 p.m., New York City time April
19, 2013. The expiration of the HSR waiting period satisfies one of the
conditions to consummate the tender offer.
The completion of the tender offer is also conditioned on approval of the
transactions by the Antimonopoly Committee of Ukraine (the "AMC") for purposes
of compliance with applicable Ukrainian antimonopoly law and the tender of a
majority of the outstanding shares of common stock of Obagi (on a fully
diluted basis). A joint application seeking approval of the tender offer and
subsequent merger was submitted by Valeant and Obagi to the AMC on March 26,
2013. Although there can be no guarantee or assurance, Valeant believes it is
possible that the parties may receive approval from the AMC in the near
future. Valeant expects to complete the tender offer and consummate the merger
promptly after the AMC's approval of the acquisition is received.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in